Azithromycin Reduces Markers of Vascular Damage in Pediatric Patients With Sickle Cell Disease.

ABSTRACT:

Background

Immunomodulatory effects of macrolides in chronic inflammation are well known. In this study, we tested our hypothesis that azithromycin (AZT) can decrease inflammation in pediatric patients with sickle cell disease (SCD).

Methods

The use of AZT as an anti-inflammatory agent was evaluated in double-blind, placebo-controlled, cross-over study for 8 weeks of treatment with 8 weeks of washout. Blood samples were collected before (PRE) and after (POST) each 8-week treatment period. Repeated measures analysis of variance (ANOVA) with post hoc multiple comparison procedures and Chi-square test were used for statistical analysis of the data. Complete blood count, distribution of the lymphocyte subsets, and plasma levels of markers of vascular damage were analyzed.

SUBMITTER: Uchakin PN 

PROVIDER: S-EPMC8425801 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature